{"id":"W1558355135","doi":"10.1002/cncr.28010","title":"Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial","year":2013,"lang":"en","type":"article","venue":"Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Cambridge Memorial Hospital","funders":"National Cancer Institute; Sanofi; Celgene; AstraZeneca; Chugai Pharmaceutical; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Exemestane; Everolimus; Breast cancer; Internal medicine; Quality of life (healthcare); Placebo; Discontinuation; Oncology; Hazard ratio; Clinical endpoint; Randomized controlled trial; Aromatase inhibitor; Cancer; Gynecology; Confidence interval; Tamoxifen; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003089526,0.001261598,0.002803857,0.0003497622,0.0003423548,0.001278451,0.0007198817,0.001332606,0.004141468],"category_scores_gemma":[0.002273032,0.0004591249,0.002985351,0.0003400199,0.0007537305,0.0007451472,0.0005010191,0.00284816,0.0004339853],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007038524,"about_ca_system_score_gemma":0.0008119479,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000539265,"about_ca_topic_score_gemma":0.001223804,"domain_scores_codex":[0.9986046,0.0009614991,0.00009152914,0.0001549725,0.00009146011,0.00009598705],"domain_scores_gemma":[0.9990232,0.0003048756,0.0003520906,0.00005423736,0.00004970474,0.0002159312],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9871395,0.001880967,0.001136554,0.0006696789,0.001955004,0.0000176934,0.00002503507,0.0002132219,0.0007575972,0.00005125374,0.0004419286,0.005711485],"study_design_scores_gemma":[0.9485454,0.04341786,0.005206986,0.00008297664,0.001399843,0.00003198184,0.00001641785,0.0002707021,0.0002577602,0.0001408148,0.0006153216,0.00001383859],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9735657,0.01824179,0.0004097101,0.001170431,0.0007233369,0.002192373,0.001467193,0.00006014793,0.002169207],"genre_scores_gemma":[0.9875987,0.003845894,0.0008757184,0.001138745,0.0005019681,0.002958496,0.001445879,0.00001174181,0.001622814],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004141468,"threshold_uncertainty_score":0.01633918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02037856840053433,"score_gpt":0.3230547976171125,"score_spread":0.3026762292165782,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}